Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, AVM Biotechnology is raising $14,720,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Theresa Deisher played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AVM Biotechnology

AVM Biotechnology – Providing New Solutions to Complex Disease. AVM Biotechnology is developing and advancing AVM0703, a patent-pending exclusive formulation. AVM0703 triggers the production and release of highly active and powerful novel immune cells. A single suprapharmacologic dose of AVM0703 activates the body’s production of natural supercharged gamma delta+ Natural Killer T (NKT) immune cells. These AVM-NKT cells have unique properties and appear rapidly following AVM0703 administration. While the full potential of these cells continues to be explored by AVM scientists, it is clear they could play a significant role in several conditions. At AVM Biotechnology, our mission to develop and deliver treatments that save lives and improve outcomes by unlocking the untapped potential of the body’s own immune system.

To learn more about AVM Biotechnology, visit http://avmbiotech.com/

Contact:
Theresa Deisher, Chief Executive Officer
206-906-9922
tdeisher@avmbiotech.com
https://www.linkedin.com/in/theresa-deisher-36b9818/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved